A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
Open Access
- 1 July 2012
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Gastroenterology
- Vol. 107 (7), 1051-1063
- https://doi.org/10.1038/ajg.2012.89
Abstract
OBJECTIVES: METHODS: RESULTS: CONCLUSIONS:Keywords
This publication has 22 references indexed in Scilit:
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseThe New England Journal of Medicine, 2010
- Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-AnalysisClinical Gastroenterology and Hepatology, 2009
- Methotrexate for maintenance of remission in Crohn's diseasePublished by Wiley ,2008
- Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT RegistryClinical Gastroenterology and Hepatology, 2006
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2005
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseThe New England Journal of Medicine, 2004
- Maintenance treatment of Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseThe New England Journal of Medicine, 1999
- Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology, 1995